Inhibikase Therapeutics (IKT) Shares Issued (2020 - 2025)
Historic Shares Issued for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $250932.0.
- Inhibikase Therapeutics' Shares Issued rose 3790.96% to $250932.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100.0 million, marking a year-over-year increase of 253510.66%. This contributed to the annual value of $103.5 million for FY2024, which is 111117.75% up from last year.
- Per Inhibikase Therapeutics' latest filing, its Shares Issued stood at $250932.0 for Q3 2025, which was up 3790.96% from $31621.0 recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Shares Issued ranged from a high of $99.7 million in Q4 2024 and a low of $70.0 during Q3 2023
- Over the past 5 years, Inhibikase Therapeutics' median Shares Issued value was $250932.0 (recorded in 2025), while the average stood at $11.8 million.
- As far as peak fluctuations go, Inhibikase Therapeutics' Shares Issued surged by 2205398384.96% in 2024, and later crashed by 9901.6% in 2025.
- Over the past 5 years, Inhibikase Therapeutics' Shares Issued (Quarter) stood at $35357.0 in 2021, then increased by 24.85% to $44142.0 in 2022, then crashed by 98.98% to $452.0 in 2023, then skyrocketed by 22053983.85% to $99.7 million in 2024, then plummeted by 99.75% to $250932.0 in 2025.
- Its last three reported values are $250932.0 in Q3 2025, $31621.0 for Q2 2025, and $99.7 million during Q4 2024.